Dr. John Arnold, Ph.D., RPh, an associate professor of pharmaceutical sciences at the McWhorter School of Pharmacy, comes back to Healthy Dose® to discuss more about biosimilar agents. Dr. Arnold will help to answer why biosimilar agents will be more cost effective, the history of why biosimilar agents came to be, who can help you to know when biosimilar agents are available and if these medications can be interchangeable or substituted easily at the pharmacy.
Listen now below to Tuesday’s new Healthy Dose® episode which aired on 11-15-16 at 5pm on WVSU FM91.1 Birmingham!
DID YOU KNOW?
Those who are Type 1 or Type 2 diabetic and on long acting insulin. Insulin glargine has a biosimilar agent coming soon, called Basaglar®, that was approved by the FDA and your insurance may be preferring the biosimilar instead of brand name Lantus® – check with your insurance company today to find out what they will cover in 2017. Click here to find out more
For those who have multiple inflammatory conditions and on Humira®, the FDA has also approved a biosimilar called Amjevita®. Click here for more